<html><body><h2>Case: 1440249</h2><h3> CDS Time: 1969-07-21</h3>
<patient name=1440249>
69.0 year old White_Non-Hispanic Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">69</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">162</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">3</td><td width="200">1966-7-29</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">49</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Chloride</td><td width="200">104.0</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">27</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">88</td><td width="200">1969-7-21</td></tr>
<tr><td width="200">BNP</td><td width="200">5847.0</td><td width="200">1966-7-25</td></tr>
<tr><td width="200">Weight</td><td width="200">220</td><td width="200">1969-7-21</td></tr>
<tr><td width="200">HbA1C</td><td width="200">6</td><td width="200">1966-7-26</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">134</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">109</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">SGOT</td><td width="200">44</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">146</td><td width="200">1969-7-21</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">1</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Height</td><td width="200">71</td><td width="200">1969-1-28</td></tr>
<tr><td width="200">Potassium</td><td width="200">4</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">109</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">BUN</td><td width="200">44</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">HCT</td><td width="200">35</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">HGB</td><td width="200">12</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Sodium</td><td width="200">143</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Albumen</td><td width="200">3</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Creatinine</td><td width="200">3.2</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">6</td><td width="200">1966-7-26</td></tr>
<tr><td width="200">Pulse</td><td width="200">81</td><td width="200">1969-7-21</td></tr>
<tr><td width="200">PLT</td><td width="200">216</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">WBC</td><td width="200">15</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">eGFR</td><td width="200">38</td><td width="200">1967-1-30</td></tr>
<tr><td width="200">SGPT</td><td width="200">43</td><td width="200">1969-4-28</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1969-7-21</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1969-6-3</td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
<tr><td width="200">Race</td><td width="200">White_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Heart_Failure</td><td width="200"></td><td width="200">1969-7-21</td></tr>
<tr><td width="200">Hyperlipidemia</td><td width="200"></td><td width="200">1969-7-21</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1969-7-21</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1969-7-21</td></tr>
</table>
<p><b>Medications:</b> aspirin(0.0) lisinopril(20.0) nitrate(1.5) carvedilol(37.5) amiodarone(200.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[Treatment_Systolic_BP(146/null) && Treatment_Diastolic_BP(88/null)]()</td></tr>
<tr><td width="200">Renal_insufficiency_w_creat>=2.1</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(3.2/1969-4-28)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension K >=3.5</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[presence of isolated systolic hypertension && Potassium(3.6/1969-4-28)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(27.0/1969-4-28)]()</td></tr>
<tr><td width="200">Heart Failure and BP not controlled</td>
<td width="200"></td>
<td width="200"> Heart Failure[presence of heart failure && BP not adequately controlled based on most recent BPTreatment_Systolic_BP(146/null)]()</td></tr>
<tr><td width="200">On Amiodarone</td>
<td width="200"></td>
<td width="200"> Amiodarone[amiodarone]()</td></tr>
<tr><td width="200">MI (BP not controlled)</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(146/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Age(69.0/1970-1-1) && Sex(Male)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(38.0/1967-1-30)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(38.0/1967-1-30)]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(69.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(3.6/1969-4-28) && presence of MI]()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1969-06-03</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1969-07-21</td>
<td width="200"> Heart_Failure()</td></tr>
<tr> <td width="200"></td>
<td width="200">1969-07-21</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1969-07-21</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(3.6/1969-4-28) && presence of MI]()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1969-07-21</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(3.6/1969-4-28) && presence of MI]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1969-07-21</td>
<td width="200"> Hyperlipidemia()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">VA/JNC-VII Hypertension Guideline</h1>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(presence of diagnosis of hypertension && absence of renovascular disease && no diagnosis of pregnancy && Absense of Secondary Hypertension && absence of spinal cord injury && absence of narcolepsy && Not taking cyclosporine && Not taking spironolactone && Not taking minoxidil && absence of renovascular disease && absence of IHSS && Absence of Ascites && Not off guideline && not taking tacrolimus && absence of transplant recipient && Absence of a dialysis procedure code)</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of TOD/CCD)</i>]
</ul>
<b>Scenario choice:</b> on two or three anti-hypertensive drugs
<p>
<b>Goal:</b> SBP < 140 and DBP < 90(absence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Systolic_BP(146/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: amiodarone, nitrate, carvedilol, lisinopril
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.
</ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>creatinine > ULN, check creatinine <font color=FF0000>preferred</font></b>(rule in criterion<i> creatinine > upper limit of normal</i> evaluate to <b> true</b> because <i>Creatinine(3.2/1969-4-28)</i>)])
Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li><b>risk group C message(on med), absence of DM <font color=FF0000>preferred</font></b>(rule in criterion<i> risk group C</i> evaluate to <b> true</b> because <i>risk group C</i>)])
This patient has clinically manifest cardiovascular disease or target organ damage (Risk Group C per JNC6).  The largest benefit of anti-hypertensive therapy is seen in patients with the highest baseline risk of cardiovascular disease, therefore this patient should be considered for prompt pharmacologic therapy, even if the BP is in the high-normal range.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>On beta blocker hyperlipidemia <font color=FF0000>preferred</font></b>(rule in criterion<i> beta blocker being used</i> evaluate to <b> true</b> because <i>beta blocker being used</i>)])
Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: amiodarone, nitrate, carvedilol, lisinopril
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>two or three drug-therapy choices</b><br>
<ul>
<li><b>Blood pressure not adequately controlled. Intensify drug treatment <font color=FF0000>preferred</font></b>(strict rule-in condition<i> BP not adequately controlled based on most recent BP</i> evaluate to <b> true</b> because <i>BP not adequately controlled based on most recent BPTreatment_Systolic_BP(146/null)</i>)])
Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.
</ul>
<li><b>step up choices</b><br>
<ul>
<li><b>evaluate increasing dose (no MI, verapamil/diltz) <font color=FF0000>preferred</font></b>(strict rule-in condition<i> there exists non-contraindicated drug not at maximum dose</i> evaluate to <b> true</b> because <i>there exists non-contraindicated drug not at maximum dose</i>)])

<li><b>evaluate new drug to prescribe <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>increase dose considerations</b><br>
<ul>
</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>Thiazide Diuretic (HCTZ)<ul><li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(38.0/1967-1-30)])  taking >= 2 anti hypertensive meds(Combination therapy for HTN[Antihypertensive_Agents]) </font><li>Relative indications:  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(146/null) && presence of myocardial infarction]) <li>HCTZ dosing message and CR>2.0(While most patients do not benefit from doses of HCTZ above 25 mg, patients with mild renal insufficiency may have added benefit from higher doses both for hypertension and fluid management.)<li>Urinary incontinence and ADD HCTZ(There is little information about the likelihood that introduction of low-dose thiazides will adversely affect bladder function.  Follow individual patient response to treatment.)<li>preference: preferred</ul><li>Cardioselective Beta Blocker (metoprolol)<ul><li>Drugs with bad interactions:  Alpha_beta_blockers(carvedilol) <li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction)  Heart_Failure(Heart_Failure) </font><li>Relative indications:  Coronary_Artery_Disease(Coronary_Artery_Disease)  CKD by eGFR or ICD9 codes(CKD[eGFR(38.0/1967-1-30)]) <li>Relative contraindications:  On Amiodarone(Amiodarone[amiodarone]) <li>preference: ruled out</ul><li>Angiotensin II Receptor Blocker (irbesartan)<ul><li>Drugs with bad interactions:  ACE_Inhibitors(lisinopril) <li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(38.0/1967-1-30)]) </font><li>Relative indications:  Heart_Failure(Heart_Failure) <li>preference: ruled out</ul><li>DHP Calcium Channel Blocker (felodipine, nifedipine SA)<ul><li>Drugs to partner:  Beta-Blockers(carvedilol) <li>Relative indications:  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(146/null) && presence of myocardial infarction]) <li>preference: preferred</ul><li>Alpha Blocker (terazosin)<ul><li>preference: neutral<li>No comment</ul><li>(non-DHP) Calcium Channel Blocker (diltiazem)<ul><li>Drugs with bad interactions:  Beta-Blockers(carvedilol) <li>Relative indications:  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(146/null) && presence of myocardial infarction])  CKD by eGFR or ICD9 codes(CKD[eGFR(38.0/1967-1-30)]) <li>Relative contraindications:  Heart_Failure(Heart_Failure)  On Amiodarone(Amiodarone[amiodarone]) <li>preference: ruled out</ul><li>Potassium Sparing Diuretic <ul><li>Relative contraindications:  Renal_insufficiency_w_creat>=2.1(Renal Insufficiency[Creatinine(3.2/1969-4-28)]) <li>preference: neutral</ul><li>ACE Inhibitor (lisinopril)<ul><li>Already being used<li><font color=FF0000>Compelling indications:  Heart_Failure(Heart_Failure)  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(146/null) && presence of myocardial infarction])  CKD by eGFR or ICD9 codes(CKD[eGFR(38.0/1967-1-30)]) </font><li>preference: ruled out</ul></ul></body></html>